We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+13.08%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$116M
AUM Growth
+$5.74M
Cap. Flow
-$1.64M
Cap. Flow %
-1.41%
Top 10 Hldgs %
96.01%
Holding
17
New
4
Increased
3
Reduced
2
Closed
3
Avg Time Held
2.6 quarters
Top 10 Avg Time Held
3.3 quarters
Top 20 Avg Time Held
2.6 quarters

Top Buys

Rank Stock Value
1
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$2.5M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.83M
3
VTGN icon
VistaGen Therapeutics
VTGN
+$1.35M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$1.2M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$839K

Top Sells

Rank Stock Value
1
MRNS icon
Marinus Pharmaceuticals, Inc
MRNS
+$3.79M
2
CMRX icon
Chimerix, Inc.
CMRX
+$2.98M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$1.54M
4
INCY icon
Incyte
INCY
+$1.16M
5
DVAX icon
Dynavax Technologies
DVAX
+$703K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PDSB icon
1
PDS Biotechnology
PDSB
$100M
$23.7M 20.4%
117,243
– –
2015 Q4
2 quarters
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$22.6M 19.4%
339,871
– –
2014 Q4
6 quarters
WVE icon
3
Wave Life Sciences
WVE
$682M
$16.2M 13.96%
784,159
– –
2015 Q4
2 quarters
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$12.4M 10.67%
1,377,497
– –
2014 Q4
6 quarters
DMTX
5
DELISTED
Dimension Therapeutics, Inc
DMTX
$12.4M 10.63%
2,059,283
– –
2015 Q4
2 quarters
DVAX icon
6
DELISTED
Dynavax Technologies
DVAX
$6.63M 5.71%
454,881
-41,161
-8% -$703K
2014 Q4
6 quarters
DERM icon
7
DELISTED
Dermira, Inc.
DERM
$5.75M 4.95%
196,544
+12,660
+7% +$349K
2015 Q2
4 quarters
ALDR
8
DELISTED
Alder Biopharmaceuticals
ALDR
$4.76M 4.1%
190,806
-57,000
-23% -$1.54M
2014 Q4
6 quarters
SAGE icon
9
DELISTED
Sage Therapeutics
SAGE
$4.73M 4.07%
156,958
+14,388
+10% +$480K
2016 Q1
1 quarter
AVEO
10
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.49M 2.14%
+259,067
New +$2.5M
2016 Q2
0 quarters
KPTI icon
11
Karyopharm Therapeutics
KPTI
$13.7M
$1.5M 1.29%
14,863
+14,048
+1,724% +$1.83M
2016 Q1
1 quarter
VTGN icon
12
VistaGen Therapeutics
VTGN
$10.5M
$1.38M 1.18%
+11,765
New +$1.35M
2016 Q2
0 quarters
ADAP
13
DELISTED
Adaptimmune Therapeutics
ADAP
$1.03M 0.89%
+127,041
New +$1.2M
2016 Q2
0 quarters
TRIL
14
DELISTED
Trillium Therapeutics Inc.
TRIL
$725K 0.62%
+80,759
New +$839K
2016 Q2
0 quarters
INCY icon
15
Incyte
INCY
$22.9B
– –
-16,000
Closed -$1.16M –
CMRX icon
16
DELISTED
Chimerix, Inc.
CMRX
– –
-582,904
Closed -$2.98M –
MRNS icon
17
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-176,143
Closed -$3.79M –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q2 2016 Portfolio in Review

As of Q2 2016, New Leaf Venture Partners held 17 positions worth $116M, up 5.2% from $110M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

New Leaf Venture Partners's Q2 2016 filing shows 4 new, 3 increased, 2 reduced and 3 closed positions. Its largest new stake was AVEO Pharmaceuticals, Inc.: 259,067 shares worth $2.49M. The largest sale was Marinus Pharmaceuticals, Inc, an estimated $3.79M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • New Leaf Venture Partners's largest Q2 2016 buy was AVEO Pharmaceuticals, Inc.: 259,067 shares worth $2.49M.
  • New Leaf Venture Partners added most to Karyopharm Therapeutics in Q2 2016, an estimated $1.83M increase.
  • New Leaf Venture Partners's biggest Q2 2016 reduction was Alder Biopharmaceuticals, cutting an estimated $1.54M.
  • New Leaf Venture Partners fully exited Marinus Pharmaceuticals, Inc in Q2 2016, selling an estimated $3.79M.
  • New Leaf Venture Partners's ten largest holdings make up 96% of its $116M portfolio in Q2 2016.
  • New Leaf Venture Partners opened 4 new positions and closed 3 in Q2 2016.
  • New Leaf Venture Partners's portfolio value rose 5.2% quarter-over-quarter to $116M.

Based on New Leaf Venture Partners's 13F filing for Q2 2016, filed 15 Aug 2016.